Clinical Trial Update: Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating anti-FLT3 CAR-T cells for relapsed/refractory acute myeloid leukemia; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-FLT3 CAR-T cells

Snippet

Sponsor: Hemogenyx Pharmaceuticals LLC | Conditions: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | Phase 1 | Status: RECRUITING